Gut-Brain Axis MS: Keio Study on T Cells | AcademicJobs
Keio University study uncovers how gut epithelial cells prime pathogenic Th17 cells causing MS neuroinflammation, opening new therapeutic paths.
No reviews yet. Be the first to rate Shohei!
Shohei Suzuki is an Assistant Professor in the Division of Gastroenterology and Hepatology at Keio University School of Medicine. He holds an M.D. from the University of Tsukuba, awarded in 2016, and completed clinical training in gastrointestinal endoscopy at Sendai City Medical Center. His research centers on mucosal immunology and immune interactions between the gut and other organs, with a particular emphasis on inflammatory bowel disease and the gut-central nervous system axis in neuroinflammatory conditions such as multiple sclerosis.
Suzuki has contributed to studies demonstrating that intestinal epithelial cells upregulate MHC class II expression to present antigens and prime pathogenic Th17 cells in the gut, which can subsequently migrate to the central nervous system. This work, published in Science Immunology in 2026, highlights potential therapeutic targets in the intestinal mucosa for autoimmune neurological diseases. He is affiliated with the Keio Global Research Institute and has been involved in collaborative research projects at Keio University School of Medicine.
Keio University study uncovers how gut epithelial cells prime pathogenic Th17 cells causing MS neuroinflammation, opening new therapeutic paths.